Form 4: Silence Therapeutics Director Reports Share Disposal

Richard Ian Griffiths, a director of Silence Therapeutics plc, reported the disposal of 100,000 American Depositary Shares on March 31, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2025, Griffiths disposed of 100,000 American Depositary Shares (ADS) at a price of $2.83 per ADS.
• Each ADS is immediately convertible into three ordinary shares.
• Following the transaction, Griffiths indirectly owns 9,861,299 ordinary shares through Cream Capital Limited, where he is a director and controlling shareholder.
• Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A director selling shares can sometimes be interpreted negatively, but the disclaimer of beneficial ownership mitigates this concern somewhat.

Negatives

• A director of Silence Therapeutics disposed of 100,000 American Depositary Shares, which could be perceived negatively by the market.

Management Comments

• Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• The disposal of shares by a director could potentially influence shareholder sentiment.

Key Dates

Keywords

Form 4, beneficial ownership, Silence Therapeutics, SLN, Richard Ian Griffiths, ADS, American Depositary Shares, Cream Capital Limited, disposal